Differential Diagnosis of STA-PSV in Thyrotoxicosis

This study has been completed.
Sponsor:
Collaborators:
Zhongda Hospital
Fudan University
Information provided by (Responsible Party):
xiaolong zhao, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT01227499
First received: October 22, 2010
Last updated: May 2, 2014
Last verified: May 2014
  Purpose

Aim: Graves's disease and thyroiditis can both characterized with thyrotoxicosis, but their clinical outcome and therapy is quiet different. Measurement of iodine uptake is the gold standard to differential diagnosis the thyroiditis or Graves's disease. But the iodine uptake is limited for its availability in china and easily influenced by medicine or food contained iodine.The blood pattern of thyroid CFDS is useful for differentiate the cause of thyrotoxicosis.Most previous studies using the descriptive pattern of thyroid CFDS is easily varied by operator subjective judgement. This study is focus on the role of peak systolic velocity of thyroid superior artery in differential diagnosis of thyrotoxicosis. Methods: Patients with thyrotoxicosis symptoms without recent medicine history were enrolled in two clinical center. Its thyroid function, iodine uptake , CFDS of thyroid and peak systolic velocity of thyroid superior artery is detected. Thyrotoxicosis is defined as TSH level below the low value of normal range. Graves disease is defined as the typical symptoms of graves disease such as graves ophthalmopathy or increased iodine uptake. Thyroiditis is defined as lack of typical symptoms of graves disease or decreased iodine uptake.We use receiver operator curve(ROC) to evaluate its diagnosis value


Condition
Thyrotoxicosis
Peak Systolic Velocity of Superior Thyroid Artery
Thyroiditis
Graves Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease

Resource links provided by NLM:


Further study details as provided by Huashan Hospital:

Primary Outcome Measures:
  • mean STA-PSV [ Time Frame: 2014-04-07 ] [ Designated as safety issue: No ]
    the mean STA-PSV

  • uptake of iodine [ Time Frame: December 1, 2013 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • PSV [ Time Frame: December 1, 2013 ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • thyroid funciton [ Time Frame: December 1, 2013 ] [ Designated as safety issue: No ]

Enrollment: 169
Study Start Date: June 2010
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • newly diagnosed without taking any antithyroid drug or beta receptor blocker with TSH level below the lower limits of reference range
  • is willing to be enrolled

Exclusion Criteria:

  • unwilling
  • taking antithyroid drug or beta receptor blocker
  • taking foods or medicine rich in iodine in 8 weeks
  • women with pregnant or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01227499

Locations
China, Shanghai
Xiaolong Zhao
Shanghai, Shanghai, China, 200040
Sponsors and Collaborators
xiaolong zhao
Zhongda Hospital
Fudan University
  More Information

Publications:
Responsible Party: xiaolong zhao, endocrinology department, Huashan Hospital
ClinicalTrials.gov Identifier: NCT01227499     History of Changes
Other Study ID Numbers: huashan001
Study First Received: October 22, 2010
Last Updated: May 2, 2014
Health Authority: China: Ministry of Health

Additional relevant MeSH terms:
Graves Disease
Thyroid Diseases
Thyroiditis
Thyrotoxicosis
Exophthalmos
Orbital Diseases
Eye Diseases
Goiter
Endocrine System Diseases
Hyperthyroidism
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 29, 2014